Glenmark Pharmaceuticals Ltd

Go Back

Glenmark Pharmaceuticals Ltd

  • Leader in the discovery of new molecules
  • Ranked among the world's top 100 pharma and biotech companies
  • Employs over 11,000 people in over 80 countries
  • Among the top Indian pharmaceutical companies

Established in 1977, Mumbai-based Glenmark Pharmaceuticals Ltd is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity). The company has a significant presence in branded generics markets across emerging economies, including India. Glenmark’s business is currently organized around four regions – India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The company employs over 11,000 people in over 80 countries. It has 14 manufacturing facilities in four countries and has six research and development (R&D) centres.


Glenmark Pharmaceuticals: Innovating Newer Molecules

2015 Launches low-price Gliptin for diabetes patients
2014 Amalgamated with Glenmark Generics Limited and Glenmark Access Limited
2012 Signs Development Agreement for worldwide collaboration with Forrest Laboratories
2011 Wins Gold Patent Award in the categories of API Formulations and Export of Bulk Drugs by Pharmexcil
2010 Enters into exclusive licensing agreement with Par Pharmaceuticals
2008 Receives recognition by Forbes as one of the 'best under a billion dollar companies in Asia'
2007 Acquires Medicamenta, a marketing and manufacturing company in Czech Republic
2006 Signs out-licensing deal in discovery R&D with Merck KGaA, Germany


Updated: August, 2015

India's pharmaceutical sector will touch US$ 45 billion by 2020.
x IBEF : India Brand Equity Foundation